Pro-Stride APS is a proprietary dual-device system whose output produces a concentrated solution of cells, platelets, growth factors, and anti-inflammatory proteins. 


  • All-Natural (from patient's own blood)

  • Clinically demonstrated effectiveness*

  • Convenient (no incubation, <20-minute processing, ambulatory)

Interleukin-1, also known as IL-1, and tumor necrosis factor alpha, also known as TNF-alpha, are the key pro-inflammatory proteins called cytokines which need to be blocked from damaging the tissue.  These inflammatory cytokines bind to the cell surface receptors on the cartilage and start the process of cartilage breakdown which ultimately leads to joint pain and damage.  


There are several naturally occurring inhibitors (anti-inflammatory proteins) of the pro-inflammatory cytokines IL-1 and TNF-alpha.  These include the interleukin-1 receptor antagonist protein (IRAP), also known as IL-1ra, SIL-1r, also known as Soluble interleukin-1 receptor and STNF-rs, known as Soluble tumor necrosis factor receptors. All of these are highly concentrated within Pro-Stride APS. 


  • Pro-Stride's output does not require an incubation period

  • Pro-Stride's output is not an autologous conditioned serum (ACS)

  • Pro-Stride's output is never frozen

Pro-Stride APS from Owl Manor

Owl Manor is a privately held medical device company dedicated to joint and soft tissue preservation of companion animals (equine and canine) through a combination of regenerative medicine, point-of-care autologous biologics, and complimentary technologies.

Owl Manor Products are intended for the direct sale to and use by licensed/practicing veterinarians


1. O’Shaughnessey et al. Autologous protein solution prepared from the blood of osteoarthritic patients contains an enhanced profile of anti-inflammatory cytokines and anabolic growth factors. JOR 2014, 32, 1349-1355.
2. Wanstrath et al., Evaluation of a Single Intra-Articular Injection of Autologous Protein Solution for Treatment of Osteoarthritis in a Canine Population. Veterinary Surgery 2016, 45 (6):764-774.

3. Bertone et al., Evaluation of a single intra-articular injection of autologous protein solution for treatment of osteoarthritis in horses. AJVR 2014, 75 (2), 141-151.
4. O’Shaughnessey et al., Blood-derived anti-inflammatory protein solution blocks the effect of IL-1β on human macrophages in vitro. Inflammation Research 2011, 60 (10), 929. 5. Woodell‐May et al., Autologous protein solution inhibits MMP‐13 production by IL‐1β and TNFα‐stimulated human articular chondrocytes. JOR 2011, 29 (9), 1320-1326.
6. King, W. et al., Human blood‐based anti‐inflammatory solution inhibits osteoarthritis progression in a meniscal‐tear rat study. JOR 2017, 35 (10), 2260-2268.

Privacy Policy                                                                                          Legal Notice

United States

© 2020 Owl Manor